An evaluation of RVX-208 for the treatment of atherosclerosis

Bibliography

• Alagona PJr, Ahmad TA. Cardiovascular disease risk assessment and prevention: current guidelines and limitations. Med Clin North Am 2015;99:711–31
   PubMed Web of Science ®Google Scholar
• Toth PP, Barylski M, Nikolic D, et al. Should low high-density lipoprotein cholesterol (HDL-C) be treated? Best Pract Res Clin Endocrinol Metab 2014;28:353–68
   PubMed Web of Science ®Google Scholar
• Barylski M, Toth PP, Nikolic D, et al. Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Pract Res Clin Endocrinol Metab 2014;28:453–61
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Gordon A, Johannson J, et al. ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovasc Drugs Ther 2012;26:181–7
   PubMed Web of Science ®Google Scholar
• Picaud S, Wells C, Felletar I, et al. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci U S A 2013;110:19754–9
   PubMed Web of Science ®Google Scholar
• Jahagirdar R, Zhang H, Azhar S, et al. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice. Atherosclerosis 2014;236:91–100
   PubMed Web of Science ®Google Scholar
• Bailey D, Jahagirdar R, Gordon A, et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol 2010;55:2580–9
   PubMed Web of Science ®Google Scholar
• Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf 2015;14:935–55
   PubMed Web of Science ®Google Scholar
• Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. position paper from an international lipid expert panel. Arch Med Sci 2015;11:1–23
   PubMed Web of Science ®Google Scholar
• Resverlogix Corp. Establishes Subsidiary: RVX Therapeutics, Inc. Available from: www.resverlogix.com [Last accessed 29 July 2005]
   Google Scholar
• Resverlogix Corp. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208. Available from: www.resverlogix.com [Last accessed 10 December 2007]
   Google Scholar
• Khmelnitsky YL, Mozhaev VV, Cotterill IC, et al. In vitro biosynthesis, isolation, and identification of predominant metabolites of 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one (RVX-208). Eur J Med Chem 2013;64:121–8
   PubMed Web of Science ®Google Scholar
• RVX 208. Drugs R D 2011;11:207–13
   PubMedGoogle Scholar
• Resverlogix Corp. RVX-208: Mechanism of Action. Available from: http://www.resverlogix.com/programs/clinical-cardiovascular-program/rvx-208-clinical-program/rvx-208-moa.html#.VXrnM0Zbfm4
   Google Scholar
• McLure KG, Gesner EM, Tsujikawa L, et al. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLoS One 2013;8:e83190
   PubMed Web of Science ®Google Scholar
• Resverlogix Corp. RVX-208 Exploratory study illustrates early potential for Alzheimer’s disease. Available from: www.resverlogix.com [Last accessed 10 November 2008] Media Release
   Google Scholar
• Resverlogix Corp. Resverlogix ASSERT trial data illustrates potential for RVX-208 in Alzheimer’s disease. Available from: www.resverlogix.com [Last accessed 25 January 2011] Media Release
   Google Scholar
• Resverlogix Corp. Dosing for RVX-208 Phase 1a clinical study completed. Available from: www.resverlogix.com [Last accessed 22 April 2008]
   Google Scholar
• Krimbou L, Jahagirdar R, Bailey D, et al. Compound RVX-208 modulates HDL-C levels and function in nonhuman primates and in early (phase I) human trials 371 abstract 1696. 81st Annual Scientific Sessions of the American Heart Association, Canada. Available from: http://scientificsessions.americanheart.org [Last accessed 8 Nov 2008]
   Google Scholar
• Resverlogix Corp. RVX-208 data demonstrates increase in functional HDL Particles. Available from: www.resverlogix.com [Last accessed 10 November 2008]
   Google Scholar
• Safety, pharmacokinetic study of RVX000222 in healthy subjects and subjects with low HDL cholesterol (NCT00768274). Available from: https://clinicaltrials.gov/ct2/show/NCT00768274?term=%22RVX+208%22&rank=6
   Google Scholar
• Gordon A, Jahagirdar R, Johansson J, et al. RVX-208 a small molecule that induces apolipoprotein A-I production progresses to phase Ib/IIa clinical trials 205 abstract. 58th Annual Scientific Session of the American College of Cardiology, Canada 2009;1021–74. Available from: http://www.sciencedirect.com [Last accessed 10 Mar 2009]
   Google Scholar
• Clinical trial for dose finding and safety of RVX000222 in subjects with stable coronary artery disease (ASSERT). NCT01058018 Available from: https://clinicaltrials.gov/ct2/show/NCT01058018?term=%22RVX+208%22&rank=3
   Google Scholar
• Nicholls SJ, Gordon A, Johansson J, et al. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol 2011;57:1111–19
   PubMed Web of Science ®Google Scholar
• Resverlogix Corp. Resverlogix presents two abstracts on analysis of the phase 2 assert clinical trial at the ESC congress 2011. Available from: www.resverlogix.com [Last accessed 1 September 2011] Media Release
   Google Scholar
• The study of quantitative serial trends in lipids with apolpoproteinA-I Stimulation (SUSTAIN). NCT01423188 Available from: https://clinicaltrials.gov/ct2/show/NCT01423188?term=%22RVX+208%22&rank=4
   Google Scholar
• ApoA-I synthesis stimulation and intravascular ultrasound for coronary atheroma regression evaluation (ASSURE I). NCT01067820 Available from: https://clinicaltrials.gov/ct2/show/study/NCT01067820?term=%22RVX+208%22&rank=5
   Google Scholar
• High Density Lipoproteins: From Biological Understanding to Clinical Exploitation. Springer Cham, Heidelberg, New York, Dordrecht, London; 2015
   Google Scholar
• A press report: communication Nicholls SJ. Available from: http://www.clinicaltrialresults.org/
   Google Scholar
• Johansson J, Leioda K, Halliday C, et al. Resverlogix Corporation. RVX-208 a selective BET protein inhibitor reduces MACE in patients with high residual risks of CVD, a post-hoc analysis. Available from: www.resverlogix.com
   Google Scholar
• Resverlogix Corporation. RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus. Available from: http://www.biospace.com/news_print.aspx?NewsEntityId=344803
   Google Scholar
• Characterization of multi-dose RVX000222 in combination with statin treatment in dyslipidemia. NCT01863225 Available from: https://clinicaltrials.gov/ct2/show/study/NCT01863225?term=%22RVX+208%22&rank=2
   Google Scholar
• The effects of RVX000222 on glucose metabolism in individuals with pre-diabetes. NCT01728467 Available from: https://clinicaltrials.gov/ct2/show/study/NCT01728467?term=%22RVX+208%22&rank=1
   Google Scholar
• Resverlogix Corp. Resverlogix reports on the beneficial effects of RVX-208 on Glucose Metabolism In Prediabetes Mellitus At The American Diabetes Association’s (ADA) Scientific Sessions in Boston, MA. Available from: www.resverlogix.com [Last accessed 8 June 2015] Media Release
   Google Scholar
• Siebel A, Trinh SK, Khan A, et al. The effects of a novel apoA-I transcriptional regulator (RVX-208) on whole plasma and HDL lipidomes. Abstract presentation at International Atherosclerosis Society, Amsterdam, The Netherlands, 26th May 2015
   Google Scholar
• France M, Schofield J, Kwok S, et al. Treatment of Homozygous Familial Hypercholesterolemia. Clin Lipidology 2014;1:101–18
   Web of Science ®Google Scholar
• Rizzo M, Otvos J, Nikolic D, et al. Subfractions and subpopulations of HDL: an update. Curr Med Chem 2014;21:2881–91
   PubMed Web of Science ®Google Scholar
• Miller R. Oral inducer of ApoA-1 synthesis RVX-208 misses end point but provides reasons for optimism. Medscape 2010
   Google Scholar
• Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, et al. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012;51:314–24
   PubMed Web of Science ®Google Scholar
• Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406–15
   PubMed Web of Science ®Google Scholar
• Kuvin JT, Dave DM, Sliney KA, et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 2006;98:743–5
   PubMed Web of Science ®Google Scholar
• Davidson MH. Apolipoprotein A-I therapy promise, challenges, and disappointment. J Am Coll Cardiol 2011;57:1120–1
   PubMed Web of Science ®Google Scholar
• Sherman CB, Peterson SJ, Frishman WH. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiol Rev 2010;18:141–7
   PubMed Web of Science ®Google Scholar
• Ibanez B, Giannarelli C, Cimmino G, et al. Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type). Atherosclerosis 2012;220:72–7
   PubMed Web of Science ®Google Scholar
• Tardif JC, Gregoire J, L’Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007;297:1675–82
   PubMed Web of Science ®Google Scholar
• Nikolic D, Mikhailidis DP, Davidson MH, et al. ETC-1002: a future option for lipid disorders? Atherosclerosis 2014;237:705–10
   PubMed Web of Science ®Google Scholar
• Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011;121:2693–708
   PubMed Web of Science ®Google Scholar
• Shah PK. Atherosclerosis: targeting endogenous apo A-I--a new approach for raising HDL. Nat Rev Cardiol 2011;8:187–8
   PubMed Web of Science ®Google Scholar
• Asztalos BF, Collins D, Cupples LA, et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2005;25:2185–91
   PubMed Web of Science ®Google Scholar
• Resverlogix Corp. Resverlogix reports on the beneficial effects of RVX-208 on glucose metabolism in prediabetes mellitus at the american diabetes association’s (ADA) Scientific Sessions in Boston, MA. Available from: www.resverlogix.com [Last accessed 1 June 2015]
   Google Scholar